This compound is a potent inhibitor of the hepatitis C virus (HCV) NS5A protein, playing a critical role in antiviral therapy. It is used as an active pharmaceutical ingredient in treatments for chronic hepatitis C infection. Due to its high potency and broad genotypic coverage, it is effective against multiple HCV genotypes, particularly genotype 1. The compound works by disrupting viral RNA replication and assembly of new viral particles, significantly reducing viral load in patients. It is typically administered in combination with other antiviral agents, such as NS3/4A protease inhibitors or NS5B polymerase inhibitors, to enhance efficacy and reduce the risk of resistance. Its use has contributed to high cure rates in HCV-infected individuals, including those with advanced liver disease or prior treatment failure. The compound’s design allows for once-daily dosing, improving patient compliance in long-term therapy regimens.